A prospective randomized, double blind, placebo-controlled, safety and efficacy study of
metformin as add-on therapy in abdominal aortic aneurysm (AAA)
OBJECTIVES Primary Objective
- To demonstrate treatment efficacy of metformin in AAA in comparison to placebo or active
comparator, as measured by growth of the AAA maximum diameter at 12 months Secondary
Objectives
- To asses inflammatory cytokines and parameters of neutrophil activation in AAA in
response to metformin treatment by glucose
- insulin
- Interleukin-6
- markers of neutrophil activation (MPO, elastase, NGAL)
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Medical University of Vienna
Collaborators:
Merck Gesellschaft mbH, Zimbagasse 5, 1147 Vienna, Austria Merck Serono GmbH, Germany